Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT
Join this webinar to explore the latest trends and strategies in Integrated Delivery Networks (IDNs). Industry experts will share insights to help manufacturers navigate the IDN landscape, optimize partnerships, and drive growth. Don't miss this opportunity for valuable knowledge and actionable insights!
Register Free: https://www.pharmexec.com/pe/idn-trends
Event Overview:
The healthcare industry is evolving rapidly, and Integrated Delivery Networks (IDNs) are at the forefront of these changes. This exclusive webinar is designed to arm manufacturers with emerging trends, insights and strategies essential for thriving in the evolving IDN landscape. During the webinar, a panel of industry experts will delve into how IDNs operate and what motivates them, offering guidance on navigating this complex terrain, optimizing partnerships and capitalizing on emerging opportunities to drive growth and enhance patient outcomes.
Attendees will walk away with an understanding of IDN market dynamics, operational nuances and best practices supporting collaboration. This webinar promises to deliver invaluable knowledge and actionable insights, empowering participants to master the complexities of the IDN market, forge robust partnerships, and propel their business growth to new heights.
Key Learning Objectives
Join this webinar and learn more about:
Who Should Attend
C-Suite, Vice President and Director positions within the following:
Speakers:
Faruk Abdullah
President, Professional Services and Chief Business Officer
EVERSANA
Faruk leads EVERSANA’s Professional Services division, which includes multiple advisory teams and the Value & Evidence Service line. He is responsible for driving growth and accelerating go-to-market efforts for EVERSANA. His career spans more than 20 years in corporate strategy and business development, customer engagement, entrepreneurship and technology. Most recently in EVERSANA, he led the growth and expansion of the EVERSANA CONSULTING team across the North American and European regions. Prior to joining EVERSANA, he was a senior leader at various consulting firms and technology companies, helping contribute to the successful development and launch of products across therapeutic and medical device categories. He holds a bachelor’s degree in electrical engineering from Northwestern University and a Master of Business Administration from Harvard Business School.
Matt Wilkins
Senior Director, Provider Networks and Strategic Accounts
G1 Therapeutics
Krista Pinto
President, Deployment Solutions
Eversana
With more than 25 years of experience in the pharmaceutical industry, Krista leads EVERSANA’s Deployment Solutions service line. Propelled with power of data, analytics and digital technology, Krista is transforming the strategy, activation and impact of field-based commercial, medical and market access teams to drive stronger program performance for therapies worldwide. Recently recognized as a MM&M Hall of Femme Honoree and a two-time Rising Star by the Healthcare Businesswoman’s Association, Krista holds a Bachelor’s Degree from the University of Delaware.
Register Free: https://www.pharmexec.com/pe/idn-trends
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.